PROCEPT BioRobotics Azioni (NASDAQ: PRCT)

Ultime notizie per PROCEPT BioRobotics (NASDAQ:PRCT) Azioni

PROCEPT BioRobotics

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Long Ideas

News

Markets

Media

Trading Ideas

PRCT

Jim Cramer elogia Target per il suo rendimento del 3% e risultati finanziari eccellenti: ecco perché è un&#39;opportunità imperdibile!

Jim Cramer elogia questo titolo: &#34;Il rendimento del 3% è fantastico!&#34;

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics Corp

Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.23) by 39.13 percent. This is a 55.56 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $37.530 million which beat the analyst consensus estimate of $36.670 million by 2.34 percent. This is a 6.86 percent decrease over sales of $40.296 million the same period last year.

Earnings

Earnings Beats

NRDY

Nerdy Q3 2024 GAAP EPS $(0.14) Beats $(0.23) Estimate, Sales $37.530M Beat $36.670M Estimate

FormFactor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) and Advantest Corporation (TSE: 6857) announced today a strategic partnership to develop a novel test cell and measurement system designed for high-volume production of silicon photonics (SiPh) and co-packaged optics (CPO) devices. This collaboration is driven by the revolution in AI data center architectures, which require ever-increasing bandwidth while reducing power consumption. Silicon photonics is rapidly gaining traction in data centers for its ability to enable fast data transmission through optical signals, surpassing traditional electrical methods. This new test cell integrates the latest innovations from both companies, equipping photonics device developers with the tools they need to scale up volume production.

FORM

FormFactor And Advantest Partner On Silicon Photonics Wafer-Level Test Cell To Enable High-Volume Manufacturing

ARKO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKO#NASDAQ">ARKO</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.12 by 41.67 percent. This is a 58.82 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $2.28 billion which missed the analyst consensus estimate of $2.41 billion by 5.44 percent. This is a 13.08 percent decrease over sales of $2.62 billion the same period last year.

Earnings Misses

ARKO

ARKO Q3 EPS $0.07 Misses $0.12 Estimate, Sales $2.28B Miss $2.41B Estimate

Offerings

PRPH

ProPhase Labs Announced That Intends To Sell Shares Of Its Common Stock In An Underwritten Public Offering; Terms Not Disclosed

Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) is looking for Q4 Adj EPS of $0.07 vs $0.07 analyst estimate. seessales of $60.000 million-61.000 million vs $60.28 million estimate.

Guidance

Definitive Healthcare Sees Q4 Adj EPS $0.07 vs $0.07 Est; Sees Sales $60.000M-61.000M vs $60.28M Est

Management

NWSA

News Corp Appoints Lavanya Chandrashekar As CFO; Succeeds Susan Panuccio

Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) raises FY2024 Adj EPS guidance from $0.32-0.34 to $0.34-0.35 vs $0.33 analyst estimate. Raises FY2024 sales outlook from $247.00 million-251.00 million to $250.00 million-251.00 million vs $249.23 million estimate.

Definitive Healthcare Raises FY2024 Adj EPS Guidance from $0.32-0.34 to $0.34-0.35 vs $0.33 Est; Raises FY2024 Sales Guidance from $247.00M-251.00M to $250.00M-251.00M vs $249.23M Est

TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $0.27 by 177.78 percent. The company reported quarterly sales of $83.800 million which beat the analyst consensus estimate of $82.870 million by 1.12 percent. This is a 1.32 percent increase over sales of $82.712 million the same period last year.

TBRG

TruBridge Q3 2024 Adj. EPS $(0.21) Misses $0.27 Estimate, Sales $83.800M Beat $82.870M Estimate

ClearPoint Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) affirms FY2024 sales outlook from $30.00 million-33.00 million to $30.00 million-33.00 million.

CLPT

ClearPoint Neuro Affirms FY2024 Sales Guidance from $30.00M-33.00M to $30.00M-33.00M

Nephros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEPH#NASDAQ">NEPH</a>) reported quarterly sales of $3.50 million which met the analyst consensus estimate. This is a 6.47 percent decrease over sales of $3.74 million the same period last year.

NEPH

Nephros Q3 Sales $3.50M Inline

SYNA

Synaptics Sees Q2 2025 Revenue $265M +/- $15M

TPI Composites (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.15) by 460 percent. This is a 50.88 percent increase over losses of $(1.71) per share from the same period last year. The company reported quarterly sales of $380.76 million which beat the analyst consensus estimate of $367.90 million by 3.50 percent. This is a 2.12 percent increase over sales of $372.86 million the same period last year.

TPIC

TPI Composites Q3 2024 Sales $380.76M Beat $367.90M Estimate

One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) raises FY2024 sales outlook from $700.00 million-740.00 million to $844.00 million-864.00 million.

STKS

One Group Hospitality Raises FY2024 Sales Guidance from $700.00M-740.00M to $844.00M-864.00M

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) raises FY2024 sales outlook from $140.00 million-145.00 million to $143.00 million-145.00 million.

ADPT

Adaptive Biotechnologies Raises FY2024 Sales Guidance from $140.00M-145.00M to $143.00M-145.00M

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 47.5 percent increase over losses of $(0.40) per share from the same period last year.

RGLS

Regulus Therapeutics Q3 EPS $(0.21) Misses $(0.17) Estimate

Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) reported its first-quarter results after Thursday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/b41823677/affirm-reports-first-fiscal-quarter-2025-results">figures from the quarter.   </a>
The Details: Affirm reported quarterly losses of 31 cents per share, which beat the analyst consensus estimate for losses of 35 cents. Quarterly revenue came in at $698.47 million which beat the analyst consensus estimate of $664.01 million and is an increase over sales of $496.54 million from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
&#8220;We continued driving accelerated growth while delivering consistent credit outcomes and managing the business to our target of 3-4% RLTC as a percentage of GMV, which stood at 3.8% this quarter. Year-over-year GMV growth re-accelerated, and growth in active consumers accelerated for the third consecutive quarter,&#8221; said Max Levchin, Affirm&#8217;s CEO.
&#8220;Transactions per active consumer grew 25% year over year to 5.1, and trailing 12-month GMV per active consumer grew 11% year over year to $1,500. We continue to expect to reach GAAP Operating Income profitability in FQ4'25,&#8221; Levchin added.
Outlook:&nbsp;Affirm sees second-quarter revenue of between $770 million and $810 million and fiscal year 2025 GMV of more than $34 billion. 
AFRM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affirm shares are down 0.71% after-hours at $48.45 at the time of publication Thursday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Movers

AFRM

Affirm Reports Better-Than-Expected Q1 Results: Details

WIIM

INOD

Innodata shares are trading higher after the company reported better-than-expected Q3 financial results.

Lions Gate Entertainment Corporation Class B Non-Voting Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.65) by 33.85 percent. The company reported quarterly sales of $948.600 million which missed the analyst consensus estimate of $956.789 million by 0.86 percent. This is a 6.63 percent decrease over sales of $1.016 billion the same period last year.

Lions Gate Entertainment Corporation Class B Non-Voting Shares

LGF/B

Lions Gate Entertainment Corporation Class B Non-Voting Shares Q2 2025 Adj. EPS $(0.43) Beats $(0.65) Estimate, Sales $948.600M Miss $956.789M Estimate

Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.58) by 27.59 percent. The company reported quarterly sales of $2.17 million which beat the analyst consensus estimate of $648.50 thousand by 234.62 percent. This is a 134.85 percent increase over sales of $924.00 thousand the same period last year.

DNTH

Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate

89bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(0.64) by 117.19 percent. This is a 208.89 percent decrease over losses of $(0.45) per share from the same period last year.

ETNB

89bio Q3 EPS $(1.39) Misses $(0.64) Estimate

Biggest stock movers Monday: DJT, crypto stocks, and more

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on PROCEPT BioRobotics (PRCT – Research Report). The associated price target rem...

Strong Financial Performance and Growth Potential Drive Buy Rating for PROCEPT BioRobotics

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Boeing (BA) will offer 90M shares of c...

Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz

PROCEPT BioRobotics announces proposed offering of common stock

Procept BioRobotics (PRCT) announced the commencement of an underwritten public offering of $175M of shares of its common stock. A selling stockhol...

Procept BioRobotics announces $175M common stock offering

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Hold rating on PROCEPT BioRobotics (PRCT – Research Report). The company's sh...

BTIG Remains a Hold on PROCEPT BioRobotics (PRCT)

PROCEPT BioRobotics (PRCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mike Kratky ...

Strong Future Potential and Resilience: PROCEPT BioRobotics as a Compelling Hypergrowth MedTech Story

The deal priced below last closing price of $96.69. BofA, Piper Sandler and Morgan Stanley are acting as joint book running managers for the offeri...

Procept BioRobotics 1.92M share Spot Secondary priced at $91.00

Truist raised the firm's price target on Procept BioRobotics (PRCT) to $105 from $95 and keeps a Buy rating on the shares. After a "strong" Q3 earn...

Comments

PROCEPT BioRobotics

Notizie

Ultime notizie per PROCEPT BioRobotics (NASDAQ:PRCT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO